(S)-tert-Butyl (5-oxopyrrolidin-3-yl)carbamate

Catalog No. :
ACHXNE245
CAS No. :
672883-23-7
Molecular Formula :
C9H16N2O3
Molecular Weight :
200.24

IUPAC Name:tert-butyl (S)-(5-oxopyrrolidin-3-yl)carbamate

(S)-tert-Butyl (5-oxopyrrolidin-3-yl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$65.00Login to see priceIn stockInquiry
1g95%$162.00Login to see priceIn stockInquiry
5g95%$604.00Login to see priceIn stockInquiry
25g95%$2929.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(S)-tert-Butyl (5-oxopyrrolidin-3-yl)carbamate
IUPAC Nametert-butyl (S)-(5-oxopyrrolidin-3-yl)carbamate
MDL No.MFCD20257110
Molecular FormulaC9H16N2O3
Molecular Weight200.24
SMILESO=C(OC(C)(C)C)N[C@@H](C1)CNC1=O
InChI KeyPFHVTCWJHBHEFA-LURJTMIESA-N
Synonym(S)-tert-Butyl (5-oxopyrrolidin-3-yl)carbamate | 672883-23-7 | (S)-tert-butyl 5-oxopyrrolidin-3-ylcarbamate | tert-butyl N-[(3S)-5-oxopyrrolidin-3-yl]carbamate | MFCD20257110 | (S)-(5-Oxo-pyrrolidin-3-yl)-carbamic acid tert-butyl ester | Carbamic acid, [(3S)-5-oxo-3-
CAS No.672883-23-7
PubChem CID45091936

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P280-P305+P351+P338-P310

Synthetic Route by SureRoute

1. ACHXNE245 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACHXNE245 route product structure diagram
    ACHXNE245672883-23-7 In Stock
Inquiry

2. ACHXNE245 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACQNSP163 route compound structure diagram
    ACQNSP163672883-63-5 In Stock
  4. Then
  5. ACHXNE245 route product structure diagram
    ACHXNE245672883-23-7 In Stock
Inquiry

Comments (0)